In this episode of The Cancer SIGNAL, Nima Nabavizadeh, MD, an associate professor of radiation medicine at Oregon Health & Science University (OHSU) and the chief medical officer at the Cancer Early Detection Advanced Research Center (CEDAR) at OHSU, joins host Susanna Quinn to share the results from the groundbreaking GRAIL PATHFINDER 2 clinical trial unveiled at the European Society for Medical Oncology (ESMO 2025) Congress. As the principal investigator for the trial, which examined the safety and performance of the Galleri multi-cancer early detection test, Dr. Nabavizadeh discusses why the findings are pivotal for patients and could potentially redefine early cancer detection.

Watch the full episode on YouTube: https://youtu.be/owhDC8vH1hw

Help shape future episodes by taking our survey: https://bit.ly/3sQkbrN

Transcripts: https://grail.com/podcast/

Sign up for GRAIL’s newsletter: https://grail.com/newsletter-signup/

The Galleri test does not detect a signal for all cancers. Not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.

See Important Safety Information: http://bit.ly/33m8pFa

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

30 - PATHFINDER 2 study results from ESMO 2025 with principal investigator Nima Nabavizadeh, MD

The Cancer SIGNAL